Sublinox (Edluar) approved in Canada

| Source: Orexo AB Orexo AB 

Sublinox (Edluar) approved in Canada

 

Uppsala, Sweden, July 25 2011 - The insomnia drug Sublinox (Edluar) has
been approved in Canada. Meda and its partner Valeant expect to begin
the launch in the fourth quarter 2011.

Sublinox will be marketed by the joint venture between Meda and Valeant,
Meda Valeant Pharma Canada Inc. Meda has global rights to the drug and
markets it in the USA since 2009 under the name Edluar. Orexo, who has
developed the drug, is entitled to royalties on sales.
The approval is for short-term treatment of insomnia. Sublinox is based
on Orexo's sublingual tablet technology. The drug is placed under the
tongue where it rapidly disintegrates and the active substance zolpidem
is absorbed through the oral mucosa.

For further information, please contact:

Anders Lundström, President and CEO, Orexo AB

Tel: +46 706 67 22 66

Email: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

About Sublinox/Edluar

Sublinox (Edluar in the USA) is based on Orexo's sublingual tablet
technology and the active substance zolpidem and offers treatment for
short-term insomnia. The tablet is placed under the tongue where it
rapidly dissolves and the active substance is absorbed through the
mucous membrane. The drug is approved in the USA for the treatment of
short-term insomnia.

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of break through cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at
www.orexo.com (http://www.orexo.com/).

Note
Orexo AB (publ) discloses the information provided in this press release
pursuant to the Securities Markets Act. The information was provided for
public release on 25 July 2011 at 08:00 CET. This press release has been
prepared in both Swedish and English. In the event of any discrepancy in
the content of the two versions, the Swedish version shall take
precedence.

 

 

Attachments